Author: Alistair Fothergill - Page 2

GLP-1 agonists, originally for diabetes, now help with significant weight loss and reduce heart risks. Learn how drugs like semaglutide and tirzepatide work, their benefits, side effects, and real-world impacts on health.

Compulsory licensing allows governments to override patents for public health needs, ensuring affordable medicines. Learn how it works, real-world examples, and the debate between innovation and access.

Learn how to safely request a lower-cost therapeutic alternative medication to save hundreds per month without sacrificing effectiveness. Real strategies, real savings, backed by clinical guidelines.

Warfarin works best when your vitamin K intake stays steady. Learn which foods affect your blood thinning, why consistency beats restriction, and how to avoid dangerous INR swings with simple daily habits.

The FDA requires generic drug labels to match brand-name labels exactly, with few exceptions. This ensures patient safety but creates delays in updating critical safety information. Learn how the system works - and why it's under pressure to change.

Hypersensitivity pneumonitis causes cough and breathlessness from inhaled environmental triggers like bird dust or mold - not medications. Early removal of the trigger can prevent permanent lung damage.

Pharmacogenomics reveals how your genes affect how your body processes drugs, uncovering hidden risks in drug interactions that traditional tools miss. Learn how genetic testing can prevent dangerous reactions and improve treatment safety.

ADHD treatment combines stimulants, non-stimulants, and behavioral strategies for the best results. Learn how each works, their side effects, and what really helps people manage symptoms long-term.

A drug formulary is your insurance plan's list of covered prescriptions. Learn how tiers, restrictions, and exceptions affect your costs - and how to save money on medications.

Generic drug exclusivity periods vary widely by country, with the U.S. using a complex mix of patents and incentives, while the EU follows a structured 8+2+1 model. These rules determine when affordable generics become available - and who pays the price.